PDL BioPharma, Inc. (PDLI) Misses Q2 EPS by 1c
PDL BioPharma, Inc. (NASDAQ: PDLI) reported Q2 adjusted EPS of $0.39, $0.01 worse than the analyst estimate of $0.40. Revenue for the quarter came in at $122.1 million versus the consensus estimate of $123.25 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- V.F. Corp. (VFC) Misses Q3 EPS by 1c, Bumps Outlook
- Advanced Micro Devices (AMD) Misses Q3 EPS by 1c; Announces Restructuring Plan
- WD-40 Co. (WDFC) Tops Q4 EPS by 13c; Guides FY15 EPS Above Views
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!